February 22, 2021
Vancouver, British Columbia–(Newsfile Corp. – February 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-clinical study to be conducted by the clinical research organization, Science in Action, an Israeli-based lab specializing in pre-clinical in vivo and in vitro R&D services.
Science in Action has confirmed that it has received ethics approval for an in vivo non-GLP toxicology study of N, N Dimethyltryptamine (DMT) (the “Study”). Both Entheon and Science in Action have applied for requisite permits in order to export, receive and research DMT drug product.
The objective of the Study is to determine the acute toxicity of IV doses of DMT in a 14-day in vivo study. The Study is being performed in advance of the Company’s human studies to evaluate DMT’s pharmaco-therapeutic profile for the treatment of substance-use disorder, anticipated to be conducted in Q4 of 2021.
“We are very excited to begin working with the acclaimed team at Science in Action in order to further characterize the toxicology profile of DMT in preparation for upcoming human trials,” said Chief Executive Officer of Entheon, Timothy Ko. “With the successful submission of our study synopsis and ethics approval obtained, we are one step closer to initiating pre-clinical work in order to further advance DMT’s profile as a therapeutic candidate to treat substance-use disorder.”